2019 ARIA Care pathways for allergen immunotherapy

Simple item page
dc.contributor.authorBousquet J.
dc.contributor.authorPfaar O.
dc.contributor.authorTogias A.
dc.contributor.authorSchünemann H.J.
dc.contributor.authorAnsotegui I.
dc.contributor.authorPapadopoulos N.G.
dc.contributor.authorTsiligianni I.
dc.contributor.authorAgache I.
dc.contributor.authorAnto J.M.
dc.contributor.authorBachert C.
dc.contributor.authorBedbrook A.
dc.contributor.authorBergmann K.-C.
dc.contributor.authorBosnic-Anticevich S.
dc.contributor.authorBosse I.
dc.contributor.authorBrozek J.
dc.contributor.authorCalderon M.A.
dc.contributor.authorCanonica G.W.
dc.contributor.authorCaraballo L.
dc.contributor.authorCardona V.
dc.contributor.authorCasale T.
dc.contributor.authorCecchi L.
dc.contributor.authorChu D.
dc.contributor.authorCosta E.
dc.contributor.authorCruz A.A.
dc.contributor.authorCzarlewski W.
dc.contributor.authorDurham S.R.
dc.contributor.authorDu Toit G.
dc.contributor.authorDykewicz M.
dc.contributor.authorEbisawa M.
dc.contributor.authorFauquert J.L.
dc.contributor.authorFernandez-Rivas M.
dc.contributor.authorFokkens W.J.
dc.contributor.authorFonseca J.
dc.contributor.authorFontaine J.-F.
dc.contributor.authorGerth van Wijk R.
dc.contributor.authorHaahtela T.
dc.contributor.authorHalken S.
dc.contributor.authorHellings P.W.
dc.contributor.authorIerodiakonou D.
dc.contributor.authorIinuma T.
dc.contributor.authorIvancevich J.C.
dc.contributor.authorJacobsen L.
dc.contributor.authorJutel M.
dc.contributor.authorKaidashev I.
dc.contributor.authorKhaitov M.
dc.contributor.authorKalayci O.
dc.contributor.authorKleine Tebbe J.
dc.contributor.authorKlimek L.
dc.contributor.authorKowalski M.L.
dc.contributor.authorKuna P.
dc.contributor.authorKvedariene V.
dc.contributor.authorLa Grutta S.
dc.contributor.authorLarenas-Linemann D.
dc.contributor.authorLau S.
dc.contributor.authorLaune D.
dc.contributor.authorLe L.
dc.contributor.authorLodrup Carlsen K.
dc.contributor.authorLourenço O.
dc.contributor.authorMalling H.-J.
dc.contributor.authorMarien G.
dc.contributor.authorMenditto E.
dc.contributor.authorMercier G.
dc.contributor.authorMullol J.
dc.contributor.authorMuraro A.
dc.contributor.authorO’Hehir R.
dc.contributor.authorOkamoto Y.
dc.contributor.authorPajno G.B.
dc.contributor.authorPark H.-S.
dc.contributor.authorPanzner P.
dc.contributor.authorPassalacqua G.
dc.contributor.authorPham-Thi N.
dc.contributor.authorRoberts G.
dc.contributor.authorPawankar R.
dc.contributor.authorRolland C.
dc.contributor.authorRosario N.
dc.contributor.authorRyan D.
dc.contributor.authorSamolinski B.
dc.contributor.authorSanchez-Borges M.
dc.contributor.authorScadding G.
dc.contributor.authorShamji M.H.
dc.contributor.authorSheikh A.
dc.contributor.authorSturm G.J.
dc.contributor.authorTodo Bom A.
dc.contributor.authorToppila-Salmi S.
dc.contributor.authorValentin-Rostan M.
dc.contributor.authorValiulis A.
dc.contributor.authorValovirta E.
dc.contributor.authorVentura M.-T.
dc.contributor.authorWahn U.
dc.contributor.authorWalker S.
dc.contributor.authorWallace D.
dc.contributor.authorWaserman S.
dc.contributor.authorYorgancioglu A.
dc.contributor.authorZuberbier T.
dc.date.accessioned2025-04-10T11:07:03Z
dc.date.available2025-04-10T11:07:03Z
dc.date.issued2019
dc.description.abstractAllergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including healthcare professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow-up of patients. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
dc.identifier.DOI-ID10.1111/all.13805
dc.identifier.urihttp://hdl.handle.net/20.500.14701/47121
dc.publisherBlackwell Publishing Ltd
dc.title2019 ARIA Care pathways for allergen immunotherapy
dc.typeReview

Files

Collections

Scopus Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize